We fight to improve the lives
of everyone affected by epilepsy

Warning message

This article was published in January 2015. The information may be out of date. Please check our epilepsy information or our site A-Z.

MHRA: new guidance for women on valproate and pregnancy

30 Jan 2015

New guidance concerning the use of sodium valproate has been released by the Medicines and Healthcare Products Regulatory Agency (MHRA). It urges medical professionals to give women better information about the risks of taking the drug

The announcement comes as the result of a European review of sodium valproate last year. The review found that up to 40 per cent of children born to women who took valproate during pregnancy experienced adverse effects. These children demonstrated problems including neurodevelopmental disorders as they grew.

Neurodevelopmental disorders are neurological conditions. They originate in childhood and can take various forms, affecting things like learning and understanding, behaviour and language. Neurodevelopmental disorders include autistic spectrum disorders (ASD) and attention deficit hyperactivity disorder (ADHD).

The findings of the European review led to stronger warnings in sodium valproate’s information leaflets. In turn, the MHRA has now called upon medical professionals to make sure that they are explaining the potential risks to an unborn child and discussing them with women with epilepsy.

Aside from the risks of neurodevelopmental disorders, sodium valproate also increases the risk that a baby may be born with a birth defect. Birth defects include things like a cleft palate.

Clinician in discussion with a pregnant womanThere are around 35,000 women in the UK who take sodium valproate. Around 375 of them become pregnant each year. These women particularly should be aware of risks and the potential implications for treatment and pregnancy.

Epilepsy Action welcomes the strengthened guidance on sodium valproate. However, the organisation stresses that – despite risks – sodium valproate is still an effective treatment option. For some women it may be the only drug that will control seizures. It should only be stopped or changed after careful consideration of the risks and benefits and discussion with a health professional.

Simon Wigglesworth, deputy chief executive at Epilepsy Action, said: “We welcome this new, stronger guidance for clinicians. For a number of years we have highlighted the need for consistent communication of the risks associated with sodium valproate for women with epilepsy. This is a positive step. It clearly outlines the advice doctors should be giving women with epilepsy about the drug.

“If you are taking sodium valproate, or your doctor is considering prescribing sodium valproate for your epilepsy, you should read the new patient advice booklet. It explains that if you are a woman of child bearing potential, your doctor should only prescribe sodium valproate if nothing else works for you. If you still have concerns after reading the information, you should urgently speak to your doctor. However, you should not stop taking your epilepsy medicine as that could be dangerous for you, and if you are pregnant, your unborn baby.”

Epilepsy Action has updated its advice and information pages in the light of the new guidance.

Read information about planning a baby.

Read more information about epilepsy medicines and pregnancy.

Read more information about contraception advice for women on sodium valproate.

You may also like...

Committee recommendation: restrict valproate in women

The Pharmacovigilance and Risk Assessment Committee (PRAC) has assessed the use of valproate in pregnant women. Their recommendations call for tighter restrictions on its use

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.